Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

Boceprevir drug can help cure hard-to-treat hepatitis C

Boceprevir drug can help cure hard-to-treat hepatitis C

Three-drug cocktail more effective against hepatitis C virus

Three-drug cocktail more effective against hepatitis C virus

Pharmasset commences PSI-7977 Phase 2b study against HCV

Pharmasset commences PSI-7977 Phase 2b study against HCV

iTherX commences ITX-5061 Phase 1b study in patients with HCV

iTherX commences ITX-5061 Phase 1b study in patients with HCV

ChronTech initiates ChronVac-C DNA vaccine Phase IIb study against HCV

ChronTech initiates ChronVac-C DNA vaccine Phase IIb study against HCV

Inhibitex fourth quarter net loss increases to $7.0 million

Inhibitex fourth quarter net loss increases to $7.0 million

Idera reports $6.0 million net loss for fourth quarter 2010

Idera reports $6.0 million net loss for fourth quarter 2010

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

BMY to present new Phase II data on investigational hepatitis C compounds at ILC

BMY to present new Phase II data on investigational hepatitis C compounds at ILC

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Scripps Health offers genetic testing to patients with Hepatitis C

Scripps Health offers genetic testing to patients with Hepatitis C

New research: Significant number of HCV patients in the U.S. does not have health insurance coverage

New research: Significant number of HCV patients in the U.S. does not have health insurance coverage

Lack of health insurance limits Hepatitis C patients' access to latest antiviral therapy

Lack of health insurance limits Hepatitis C patients' access to latest antiviral therapy

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.